Strensiq is a medication that has been developed to treat patients with hypophosphatasia, a rare genetic disorder that affects the bones and teeth. This condition is characterized by a deficiency of an enzyme called alkaline phosphatase, which leads to abnormal bone formation and mineralization.

Strensiq works by replacing the missing enzyme in patients with hypophosphatasia, helping to improve bone mineralization and reduce the risk of fractures and other complications associated with the disorder. It is administered through subcutaneous injections, typically on a regular basis as prescribed by a healthcare provider.

Clinical trials have shown that Strensiq can significantly improve bone mineralization and reduce the severity of symptoms in patients with hypophosphatasia. It has been shown to be well-tolerated and effective in both children and adults with the condition.

As with any medication, there may be potential side effects associated with Strensiq. These can include injection site reactions, allergic reactions, and other less common side effects. It is important for patients to discuss any concerns or potential side effects with their healthcare provider before starting treatment with Strensiq.

Overall, Strensiq has shown great promise in improving the quality of life for patients with hypophosphatasia. It is important for patients to work closely with their healthcare team to determine if Strensiq is the right treatment option for them and to monitor their progress while on the medication.